Climacteric · 2010 · 23 citations · 28 references
PharmacyEndocrinologyPharmacotherapyClinical PharmacologyWomen's HealthWomen's Health PharmacotherapyHormonal EvaluationMenopause CareMenopause Hormone TherapyMenopause ManagementMenopause PharmacotherapyClinical SymptomsMenopausal StatusMenopausal Symptom ReliefMenopause Symptom AssessmentMenopause Symptom ManagementOutcome MeasuresPlacebo-controlled Efficacy AssessmentPrimary Outcome Analysis
OBJECTIVE: The aim of this study was to assess the efficacy and safety of Diascorea alata for treatment of menopausal symptoms. MATERIALS AND METHODS: Two-center, randomized, double-blind, placebo-controlled clinical investigation on 50 menopausal women randomly assigned to two groups, treated for 12 months with either placebo or two sachets daily of Diascorea extracts containing 12 mg/sachet. Primary outcome measures were changes in the Greene Climacteric Scale caused by Diascorea compared with placebo; secondary outcomes were changes in plasma hormone profiles. One-way ANCOVA test was performed to investigate the significance. RESULTS: At 6 months and at the end of treatment, those women who received Diascorea showed general improvement in almost all the clinical symptoms investigated. A significant reduction was noted in the total Greene scores in the Diascorea group assessed at the end of 12 months' treatment (p < 0.01). This phenomenon was more significant for the psychological parameters of anxiety than for other parameters. Apparent improvements were noted in the parameters 'feeling tense or nervous' (p = 0.007), 'insomnia' (p = 0.004), 'excitable' (p = 0.047) and 'musculoskeletal pain' (p = 0.019) among those receiving Diascorea. Diascorea consumption also resulted in positive effects on blood hormone profiles. CONCLUSIONS: Compared with placebo, Diascorea alata improves symptoms, particularly the psychological parameters in menopausal women. Safety monitoring indicated that standardized extracts of Diascorea alata were safe during daily administration over a period of 12 months.
28
Breast cancer and hormone-replacement therapy in the Million Women Study
Valerie Beral · The Lancet · 2003 · 3K citations
Medicine, Endocrinology, Oncology +13
National Use of Postmenopausal Hormone Therapy
Adam L. Hersh, Marcia L. Stefanick, Randall S. Stafford · JAMA · 2004 · 980 citations
Urinary estrogen metabolites and breast cancer: a case-control study.
Geoffrey C. Kabat, Chee‐Jen Chang, Joseph A. Sparano et al. · PubMed · 1997 · 212 citations
Medicine, Endocrinology, Oncology +12